25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Arcutis Biotherapeutics Inc
Buy, Hold or Sell?

Let's analyze Arcutis together

I guess you are interested in Arcutis Biotherapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Arcutis Biotherapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Arcutis Biotherapeutics Inc

I send you an email if I find something interesting about Arcutis Biotherapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Arcutis (30 sec.)










1.2. What can you expect buying and holding a share of Arcutis? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.26
Expected worth in 1 year
$2.12
How sure are you?
29.2%

+ What do you gain per year?

Total Gains per Share
$0.86
Return On Investment
6.8%

For what price can you sell your share?

Current Price per Share
$12.69
Expected price per share
$11.22 - $15.21
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Arcutis (5 min.)




Live pricePrice per Share (EOD)
$12.69
Intrinsic Value Per Share
$-11.46 - $-12.95
Total Value Per Share
$-10.20 - $-11.69

2.2. Growth of Arcutis (5 min.)




Is Arcutis growing?

Current yearPrevious yearGrowGrow %
How rich?$156.6m$119.1m$45m27.4%

How much money is Arcutis making?

Current yearPrevious yearGrowGrow %
Making money-$48.8m-$67.7m$18.8m38.6%
Net Profit Margin-206.0%-1,726.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Arcutis (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#286 / 944

Most Revenue
#171 / 944

Most Profit
#828 / 944

Most Efficient
#524 / 944
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Arcutis?

Welcome investor! Arcutis's management wants to use your money to grow the business. In return you get a share of Arcutis.

First you should know what it really means to hold a share of Arcutis. And how you can make/lose money.

Speculation

The Price per Share of Arcutis is $12.69. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Arcutis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Arcutis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.26. Based on the TTM, the Book Value Change Per Share is $0.22 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.48 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Arcutis.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.33-2.6%-0.41-3.2%-0.57-4.5%-0.45-3.5%-0.39-3.1%
Usd Book Value Change Per Share-0.25-2.0%0.221.7%-0.48-3.8%0.090.7%0.050.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.25-2.0%0.221.7%-0.48-3.8%0.090.7%0.050.4%
Usd Price Per Share9.30-7.94-10.16-17.52-14.60-
Price to Earnings Ratio-6.96--5.52--4.36--11.44--9.53-
Price-to-Total Gains Ratio-37.26--10.58--20.99--26.78--26.78-
Price to Book Ratio7.38-5.74-11.16-9.60-8.00-
Price-to-Total Gains Ratio-37.26--10.58--20.99--26.78--26.78-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share12.69
Number of shares78
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.220.09
Usd Total Gains Per Share0.220.09
Gains per Quarter (78 shares)16.796.68
Gains per Year (78 shares)67.1626.72
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10675702717
2013412405344
3020119108071
40269258010798
503363250134125
604033920160152
704704590187179
805375260214206
906045930240233
1006726600267260

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.024.00.00.0%0.024.00.00.0%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%6.014.00.030.0%7.016.01.029.2%7.016.01.029.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.024.00.0%0.00.024.00.0%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%6.014.00.030.0%7.016.01.029.2%7.016.01.029.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Arcutis Biotherapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.2500.215-216%-0.479+92%0.086-391%0.053-575%
Book Value Per Share--1.2601.362-7%1.018+24%1.790-30%1.488-15%
Current Ratio--2.4576.974-65%9.162-73%13.460-82%12.899-81%
Debt To Asset Ratio--0.6420.623+3%0.689-7%0.438+47%0.556+15%
Debt To Equity Ratio--1.7921.789+0%2.778-35%1.053+70%0.883+103%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--1205859548.1001041974185.950+16%1257161200.000-4%2351517449.674-49%2351517449.674-49%
Eps---0.334-0.407+22%-0.572+71%-0.450+35%-0.389+17%
Ev To Ebitda Ratio---9.012-7.062-22%-5.232-42%-13.411+49%-13.411+49%
Ev To Sales Ratio--6.7367.714-13%85.932-92%infnan%infnan%
Free Cash Flow Per Share---0.280-0.349+25%-0.561+100%-0.402+44%-0.347+24%
Free Cash Flow To Equity Per Share---0.2770.212-231%-0.554+100%0.127-317%0.117-337%
Gross Profit Margin--1.0001.332-25%1.158-14%1.098-9%1.082-8%
Intrinsic Value_10Y_max---12.949--------
Intrinsic Value_10Y_min---11.461--------
Intrinsic Value_1Y_max---1.865--------
Intrinsic Value_1Y_min---1.832--------
Intrinsic Value_3Y_max---5.172--------
Intrinsic Value_3Y_min---4.946--------
Intrinsic Value_5Y_max---7.956--------
Intrinsic Value_5Y_min---7.422--------
Market Cap1485301050.000+22%1156011548.100960588685.950+20%1189177200.000-3%2056878677.190-44%1714065564.325-33%
Net Profit Margin---0.928-2.060+122%-17.265+1760%-11.497+1139%-9.581+932%
Operating Margin---0.779-1.797+131%-15.931+1944%-10.770+1282%-8.975+1051%
Operating Ratio--1.8732.914-36%17.091-89%11.275-83%9.396-80%
Pb Ratio10.070+27%7.3805.740+29%11.160-34%9.596-23%7.997-8%
Pe Ratio-9.494-36%-6.958-5.516-21%-4.358-37%-11.435+64%-9.529+37%
Price Per Share12.690+27%9.3007.935+17%10.160-8%17.519-47%14.599-36%
Price To Free Cash Flow Ratio-11.322-36%-8.297-6.379-23%-4.447-46%-13.237+60%-11.031+33%
Price To Total Gains Ratio-50.841-36%-37.259-10.576-72%-20.992-44%-26.778-28%-26.778-28%
Quick Ratio--3.40110.229-67%14.394-76%20.675-84%19.153-82%
Return On Assets---0.095-0.120+27%-0.188+98%-0.152+60%-0.169+78%
Return On Equity---0.265-0.363+37%-0.693+161%-0.323+22%-0.279+5%
Total Gains Per Share---0.2500.215-216%-0.479+92%0.086-391%0.053-575%
Usd Book Value--156641000.000164169250.000-5%119134500.000+31%210438250.000-26%174959000.000-10%
Usd Book Value Change Per Share---0.2500.215-216%-0.479+92%0.086-391%0.053-575%
Usd Book Value Per Share--1.2601.362-7%1.018+24%1.790-30%1.488-15%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--1205859548.1001041974185.950+16%1257161200.000-4%2351517449.674-49%2351517449.674-49%
Usd Eps---0.334-0.407+22%-0.572+71%-0.450+35%-0.389+17%
Usd Free Cash Flow---34831000.000-41950750.000+20%-65605750.000+88%-47293750.000+36%-40749208.333+17%
Usd Free Cash Flow Per Share---0.280-0.349+25%-0.561+100%-0.402+44%-0.347+24%
Usd Free Cash Flow To Equity Per Share---0.2770.212-231%-0.554+100%0.127-317%0.117-337%
Usd Market Cap1485301050.000+22%1156011548.100960588685.950+20%1189177200.000-3%2056878677.190-44%1714065564.325-33%
Usd Price Per Share12.690+27%9.3007.935+17%10.160-8%17.519-47%14.599-36%
Usd Profit---41537000.000-48883750.000+18%-67776750.000+63%-53345950.000+28%-45914500.000+11%
Usd Revenue--44755000.00034677000.000+29%12260250.000+265%9423700.000+375%7853083.333+470%
Usd Total Gains Per Share---0.2500.215-216%-0.479+92%0.086-391%0.053-575%
 EOD+5 -3MRQTTM+19 -19YOY+27 -115Y+15 -2210Y+15 -22

3.3 Fundamental Score

Let's check the fundamental score of Arcutis Biotherapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-9.494
Price to Book Ratio (EOD)Between0-110.070
Net Profit Margin (MRQ)Greater than0-0.928
Operating Margin (MRQ)Greater than0-0.779
Quick Ratio (MRQ)Greater than13.401
Current Ratio (MRQ)Greater than12.457
Debt to Asset Ratio (MRQ)Less than10.642
Debt to Equity Ratio (MRQ)Less than11.792
Return on Equity (MRQ)Greater than0.15-0.265
Return on Assets (MRQ)Greater than0.05-0.095
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Arcutis Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.233
Ma 20Greater thanMa 5011.591
Ma 50Greater thanMa 10010.260
Ma 100Greater thanMa 20010.029
OpenGreater thanClose12.250
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Fundamental data was last updated by Penke on 2024-12-05 12:50:08.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Arcutis earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Arcutis to the Biotechnology industry mean.
  • A Net Profit Margin of -92.8% means that $-0.93 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Arcutis Biotherapeutics Inc:

  • The MRQ is -92.8%. The company is making a huge loss. -2
  • The TTM is -206.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-92.8%TTM-206.0%+113.1%
TTM-206.0%YOY-1,726.5%+1,520.6%
TTM-206.0%5Y-1,149.7%+943.8%
5Y-1,149.7%10Y-958.1%-191.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-92.8%-108.6%+15.8%
TTM-206.0%-221.4%+15.4%
YOY-1,726.5%-207.4%-1,519.1%
5Y-1,149.7%-346.2%-803.5%
10Y-958.1%-470.4%-487.7%
4.3.1.2. Return on Assets

Shows how efficient Arcutis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Arcutis to the Biotechnology industry mean.
  • -9.5% Return on Assets means that Arcutis generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Arcutis Biotherapeutics Inc:

  • The MRQ is -9.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.5%TTM-12.0%+2.5%
TTM-12.0%YOY-18.8%+6.8%
TTM-12.0%5Y-15.2%+3.2%
5Y-15.2%10Y-16.9%+1.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.5%-11.6%+2.1%
TTM-12.0%-12.0%0.0%
YOY-18.8%-11.2%-7.6%
5Y-15.2%-12.6%-2.6%
10Y-16.9%-14.1%-2.8%
4.3.1.3. Return on Equity

Shows how efficient Arcutis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Arcutis to the Biotechnology industry mean.
  • -26.5% Return on Equity means Arcutis generated $-0.27 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Arcutis Biotherapeutics Inc:

  • The MRQ is -26.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -36.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-26.5%TTM-36.3%+9.8%
TTM-36.3%YOY-69.3%+33.0%
TTM-36.3%5Y-32.3%-4.0%
5Y-32.3%10Y-27.9%-4.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-26.5%-14.5%-12.0%
TTM-36.3%-16.0%-20.3%
YOY-69.3%-14.6%-54.7%
5Y-32.3%-18.5%-13.8%
10Y-27.9%-19.2%-8.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Arcutis Biotherapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Arcutis is operating .

  • Measures how much profit Arcutis makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Arcutis to the Biotechnology industry mean.
  • An Operating Margin of -77.9% means the company generated $-0.78  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Arcutis Biotherapeutics Inc:

  • The MRQ is -77.9%. The company is operating very inefficient. -2
  • The TTM is -179.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-77.9%TTM-179.7%+101.8%
TTM-179.7%YOY-1,593.1%+1,413.4%
TTM-179.7%5Y-1,077.0%+897.2%
5Y-1,077.0%10Y-897.5%-179.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-77.9%-204.0%+126.1%
TTM-179.7%-316.8%+137.1%
YOY-1,593.1%-215.6%-1,377.5%
5Y-1,077.0%-376.1%-700.9%
10Y-897.5%-480.3%-417.2%
4.3.2.2. Operating Ratio

Measures how efficient Arcutis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.87 means that the operating costs are $1.87 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 1.873. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.914. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.873TTM2.914-1.041
TTM2.914YOY17.091-14.177
TTM2.9145Y11.275-8.361
5Y11.27510Y9.396+1.879
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8732.284-0.411
TTM2.9143.198-0.284
YOY17.0913.247+13.844
5Y11.2754.651+6.624
10Y9.3966.419+2.977
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Arcutis Biotherapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Arcutis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.46 means the company has $2.46 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 2.457. The company is able to pay all its short-term debts. +1
  • The TTM is 6.974. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.457TTM6.974-4.516
TTM6.974YOY9.162-2.188
TTM6.9745Y13.460-6.487
5Y13.46010Y12.899+0.561
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4573.586-1.129
TTM6.9743.869+3.105
YOY9.1624.644+4.518
5Y13.4605.971+7.489
10Y12.8996.240+6.659
4.4.3.2. Quick Ratio

Measures if Arcutis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Arcutis to the Biotechnology industry mean.
  • A Quick Ratio of 3.40 means the company can pay off $3.40 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 3.401. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.229. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.401TTM10.229-6.828
TTM10.229YOY14.394-4.165
TTM10.2295Y20.675-10.445
5Y20.67510Y19.153+1.521
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4013.093+0.308
TTM10.2293.392+6.837
YOY14.3944.304+10.090
5Y20.6755.953+14.722
10Y19.1536.435+12.718
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Arcutis Biotherapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Arcutis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Arcutis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.64 means that Arcutis assets are financed with 64.2% credit (debt) and the remaining percentage (100% - 64.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 0.642. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.623. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.642TTM0.623+0.019
TTM0.623YOY0.689-0.065
TTM0.6235Y0.438+0.185
5Y0.43810Y0.556-0.118
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6420.346+0.296
TTM0.6230.347+0.276
YOY0.6890.313+0.376
5Y0.4380.365+0.073
10Y0.5560.383+0.173
4.5.4.2. Debt to Equity Ratio

Measures if Arcutis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Arcutis to the Biotechnology industry mean.
  • A Debt to Equity ratio of 179.2% means that company has $1.79 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Arcutis Biotherapeutics Inc:

  • The MRQ is 1.792. The company is just able to pay all its debts with equity.
  • The TTM is 1.789. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.792TTM1.789+0.003
TTM1.789YOY2.778-0.990
TTM1.7895Y1.053+0.736
5Y1.05310Y0.883+0.170
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7920.393+1.399
TTM1.7890.432+1.357
YOY2.7780.388+2.390
5Y1.0530.455+0.598
10Y0.8830.498+0.385
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Arcutis generates.

  • Above 15 is considered overpriced but always compare Arcutis to the Biotechnology industry mean.
  • A PE ratio of -6.96 means the investor is paying $-6.96 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Arcutis Biotherapeutics Inc:

  • The EOD is -9.494. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.958. Based on the earnings, the company is expensive. -2
  • The TTM is -5.516. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.494MRQ-6.958-2.536
MRQ-6.958TTM-5.516-1.441
TTM-5.516YOY-4.358-1.159
TTM-5.5165Y-11.435+5.919
5Y-11.43510Y-9.529-1.906
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.494-2.180-7.314
MRQ-6.958-2.507-4.451
TTM-5.516-3.153-2.363
YOY-4.358-3.242-1.116
5Y-11.435-5.992-5.443
10Y-9.529-6.690-2.839
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Arcutis Biotherapeutics Inc:

  • The EOD is -11.322. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.297. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.379. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.322MRQ-8.297-3.024
MRQ-8.297TTM-6.379-1.918
TTM-6.379YOY-4.447-1.932
TTM-6.3795Y-13.237+6.858
5Y-13.23710Y-11.031-2.206
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.322-2.879-8.443
MRQ-8.297-3.276-5.021
TTM-6.379-3.669-2.710
YOY-4.447-4.485+0.038
5Y-13.237-8.015-5.222
10Y-11.031-9.197-1.834
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Arcutis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 7.38 means the investor is paying $7.38 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Arcutis Biotherapeutics Inc:

  • The EOD is 10.070. Based on the equity, the company is expensive. -2
  • The MRQ is 7.380. Based on the equity, the company is overpriced. -1
  • The TTM is 5.740. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD10.070MRQ7.380+2.690
MRQ7.380TTM5.740+1.640
TTM5.740YOY11.160-5.419
TTM5.7405Y9.596-3.856
5Y9.59610Y7.997+1.599
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD10.0701.964+8.106
MRQ7.3802.056+5.324
TTM5.7402.388+3.352
YOY11.1602.460+8.700
5Y9.5963.697+5.899
10Y7.9974.324+3.673
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Arcutis Biotherapeutics Inc.

4.8.1. Institutions holding Arcutis Biotherapeutics Inc

Institutions are holding 113.512% of the shares of Arcutis Biotherapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Jennison Associates LLC9.9650.067311663497918030.7933
2024-09-30Rubric Capital Management LP9.36971.661910966672115000011.7148
2024-09-30Suvretta Capital Management, LLC9.16023.1903107215117170197.167
2024-06-30BlackRock Inc7.3670.00188622618196387729.4932
2024-09-30Vanguard Group Inc5.94870.0012696263581834513.3188
2024-09-30Polar Capital Holdings PLC5.88180.3054688437253000.077
2024-09-30State Street Corp4.82010.002156416315067889.8696
2024-09-30Franklin Resources Inc3.63150.01134250418-187761-4.2306
2024-09-30Morgan Stanley - Brokerage Accounts3.23060.00263781195-4164193-52.4102
2024-09-30Gilder Gagnon Howe & CO LLC3.03630.39543553838-62694-1.7335
2024-09-30Citadel Advisors Llc2.58970.00543031073984263.3562
2024-09-30Geode Capital Management, LLC2.11040.00192470138488682.0183
2024-09-30Ensign Peak Advisors Inc2.06490.0395241681228311013.2685
2024-09-30Cormorant Asset Management, LLC1.98641.14662325000-200000-7.9208
2024-09-30Pivotal bioVenture Partners Investment Advisor LLC1.811711.70562120508794003.89
2024-06-30Deutsche Bank AG1.6080.0079188202594200.503
2024-09-30StemPoint Capital LP1.51944.9514177831881292684.2068
2024-09-30D. E. Shaw & Co LP1.49090.0139174502473764073.2233
2024-09-30GW&K Investment Management, LLC1.36160.12681593630-74349-4.4574
2024-09-30Goldman Sachs Group Inc1.35840.0024158988278254896.9299
Total 80.312323.640794000797+3416473+3.6%

4.9.2. Funds holding Arcutis Biotherapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Polar Capital Biotech S Inc5.55342.779765000005000008.3333
2024-10-31Vanguard Total Stock Mkt Idx Inv3.0080.00173520666-68844-1.9179
2024-09-30Jennison SMid Cap Core Equity2.63590.8701308519800
2024-10-31PGIM Jennison Small Company A2.63590.7991308519800
2024-11-27SPDRÂź S&P Biotech ETF2.59190.47873033679-92070-2.9455
2024-11-27iShares Russell 2000 ETF2.52650.04292957115-6174-0.2083
2024-10-31PGIM Jennison Health Sciences Z2.33671.2876273501000
2024-09-30Jennison Health Sciences Equity2.33671.3769273501000
2024-10-31Franklin Biotechnology Discv A(acc)USD2.26881.4406265551900
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.36790.01231601085-4631-0.2884
2024-09-30Franklin Biotechnology Discovery A1.30341.5342152554500
2024-08-31MEDICAL BioHealth EUR Acc1.26051.984147530100
2024-09-30American Century U.S. Small Cap Growth1.09670.2867128362121064219.6315
2024-09-30American Century Small Cap Growth Inv1.09670.2875128362121064219.6315
2024-10-31Candriam Eqs L Biotech C USD Cap0.93550.5559109493800
2024-09-30Fidelity Small Cap Index0.92380.03661081241-7148-0.6568
2024-11-27iShares Russell 2000 Growth ETF0.81540.083695438300
2024-10-31Invesco Small Cap Value A0.77230.128990390000
2024-09-30JENNISON SMALL/MID CAP EQUITY 30.71060.89183171917944827.5113
2024-11-27iShares Biotechnology ETF0.59840.11777004407120.1018
Total 36.77514.995743043189+922577+2.1%

5.3. Insider Transactions

Insiders are holding 2.15% of the shares of Arcutis Biotherapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-12-02Howard G WelgusSELL1000012.51
2024-11-30Larry Todd EdwardsBUY10937.11
2024-11-22Patrick BurnettSELL1602310.14
2024-11-19Masaru MatsudaSELL17759.68
2024-11-15Patrick BurnettSELL10010.03
2024-11-11Terrie CurranSELL868710.85
2024-11-04Masaru MatsudaSELL50158.68
2024-11-01Howard G WelgusSELL100008.65
2024-10-02Larry Todd EdwardsSELL372510.01
2024-10-01Howard G WelgusSELL100009.26
2024-09-24David Joseph TopperSELL116269.48
2024-09-03Howard G WelgusSELL1000010.77
2024-08-19Patrick BurnettSELL17288.29
2024-08-02Masaru MatsudaSELL52209.02
2024-08-01Howard G WelgusSELL100009.87
2024-07-01Howard G WelgusSELL100009.31
2024-05-30Patrick BurnettSELL230008.75
2024-05-28Masaru MatsudaSELL17759.01
2024-05-17Larry Todd EdwardsSELL76408.98
2024-03-04Masaru MatsudaSELL376011.12
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets437,354
Total Liabilities280,713
Total Stockholder Equity156,641
 As reported
Total Liabilities 280,713
Total Stockholder Equity+ 156,641
Total Assets = 437,354

Assets

Total Assets437,354
Total Current Assets423,720
Long-term Assets13,634
Total Current Assets
Cash And Cash Equivalents 134,851
Short-term Investments 195,710
Net Receivables 60,119
Inventory 14,015
Other Current Assets 19,025
Total Current Assets  (as reported)423,720
Total Current Assets  (calculated)423,720
+/-0
Long-term Assets
Property Plant Equipment 3,246
Intangible Assets 9,792
Long-term Assets Other 596
Long-term Assets  (as reported)13,634
Long-term Assets  (calculated)13,634
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities172,426
Long-term Liabilities108,287
Total Stockholder Equity156,641
Total Current Liabilities
Short-term Debt 100,311
Short Long Term Debt 99,513
Accounts payable 19,325
Other Current Liabilities 52,790
Total Current Liabilities  (as reported)172,426
Total Current Liabilities  (calculated)271,939
+/- 99,513
Long-term Liabilities
Long term Debt 105,095
Capital Lease Obligations 3,570
Long-term Liabilities Other 420
Long-term Liabilities  (as reported)108,287
Long-term Liabilities  (calculated)109,085
+/- 798
Total Stockholder Equity
Common Stock12
Retained Earnings -1,111,155
Accumulated Other Comprehensive Income 533
Other Stockholders Equity 1,267,251
Total Stockholder Equity (as reported)156,641
Total Stockholder Equity (calculated)156,641
+/-0
Other
Capital Stock12
Cash and Short Term Investments 330,561
Common Stock Shares Outstanding 124,302
Liabilities and Stockholders Equity 437,354
Net Debt 73,327
Net Invested Capital 361,249
Net Working Capital 251,294
Property Plant and Equipment Gross 3,246
Short Long Term Debt Total 208,178



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
> Total Assets 
51,098
38,179
38,179
28,303
107,012
254,392
231,970
198,013
298,269
471,416
432,892
387,008
408,152
364,109
300,464
508,914
449,274
379,458
320,689
292,959
341,365
478,541
444,759
437,354
437,354444,759478,541341,365292,959320,689379,458449,274508,914300,464364,109408,152387,008432,892471,416298,269198,013231,970254,392107,01228,30338,17938,17951,098
   > Total Current Assets 
51,098
37,596
37,596
27,771
106,474
253,878
228,035
194,121
292,826
465,975
427,554
381,770
402,773
358,918
295,426
496,719
437,406
367,676
308,868
281,548
330,431
468,062
434,591
423,720
423,720434,591468,062330,431281,548308,868367,676437,406496,719295,426358,918402,773381,770427,554465,975292,826194,121228,035253,878106,47427,77137,59637,59651,098
       Cash And Cash Equivalents 
39,394
12,823
12,823
23,177
63,336
190,893
171,546
45,707
65,082
288,690
89,128
51,778
96,449
69,795
61,512
81,543
53,641
81,405
105,114
107,471
89,323
190,714
84,887
134,851
134,85184,887190,71489,323107,471105,11481,40553,64181,54361,51269,79596,44951,77889,128288,69065,08245,707171,546190,89363,33623,17712,82312,82339,394
       Short-term Investments 
11,546
23,039
23,039
2,000
37,929
58,426
52,429
144,005
219,359
156,237
320,236
315,492
290,610
273,806
220,657
395,420
355,948
251,000
163,557
119,642
183,463
213,769
278,167
195,710
195,710278,167213,769183,463119,642163,557251,000355,948395,420220,657273,806290,610315,492320,236156,237219,359144,00552,42958,42637,9292,00023,03923,03911,546
       Net Receivables 
0
0
0
0
0
0
0
472
510
577
399
362
362
362
0
2,431
8,458
12,769
17,207
19,417
25,807
37,154
43,411
60,119
60,11943,41137,15425,80719,41717,20712,7698,4582,43103623623623995775104720000000
       Other Current Assets 
158
0
0
2,594
5,209
4,559
4,060
3,937
7,875
19,506
17,791
14,138
14,172
14,955
13,257
13,018
10,611
13,026
11,591
20,180
19,629
13,178
14,863
19,025
19,02514,86313,17819,62920,18011,59113,02610,61113,01813,25714,95514,17214,13817,79119,5067,8753,9374,0604,5595,2092,59400158
   > Long-term Assets 
0
0
0
532
538
514
3,935
3,892
5,443
5,441
5,338
5,238
5,379
5,191
5,038
12,195
11,868
11,782
11,821
11,411
10,934
10,479
10,168
13,634
13,63410,16810,47910,93411,41111,82111,78211,86812,1955,0385,1915,3795,2385,3385,4415,4433,8923,935514538532000
       Property Plant Equipment 
0
536
536
485
491
467
3,857
3,814
5,365
5,363
5,260
5,160
5,301
5,113
4,960
4,742
4,602
4,704
4,413
4,190
3,900
3,633
3,510
3,246
3,2463,5103,6333,9004,1904,4134,7044,6024,7424,9605,1135,3015,1605,2605,3635,3653,8143,8574674914855365360
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,375
7,188
7,000
6,812
6,625
6,438
6,250
6,063
9,792
9,7926,0636,2506,4386,6256,8127,0007,1887,375000000000000000
       Other Assets 
0
47
47
47
47
47
78
78
78
78
78
78
78
78
78
78
78
0
596
0
0
0
0
0
000005960787878787878787878787847474747470
> Total Liabilities 
75,085
4,585
4,585
81,253
172,041
12,510
23,047
24,942
27,648
20,422
18,404
24,013
110,475
110,337
105,082
238,140
239,693
239,726
240,181
246,242
252,698
253,599
258,332
280,713
280,713258,332253,599252,698246,242240,181239,726239,693238,140105,082110,337110,47524,01318,40420,42227,64824,94223,04712,510172,04181,2534,5854,58575,085
   > Total Current Liabilities 
2,673
4,170
4,170
8,599
5,237
12,222
19,281
21,154
22,602
15,314
13,347
19,058
33,326
32,963
27,482
37,102
37,807
37,025
36,659
41,889
46,668
47,309
51,352
172,426
172,42651,35247,30946,66841,88936,65937,02537,80737,10227,48232,96333,32619,05813,34715,31422,60221,15419,28112,2225,2378,5994,1704,1702,673
       Short-term Debt 
0
0
0
173
178
182
80
32
0
0
106
306
433
507
582
639
657
676
695
715
1,470
756
1,554
100,311
100,3111,5547561,470715695676657639582507433306106003280182178173000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
99,513
99,51300000000000000000000000
       Accounts payable 
1,801
2,025
2,025
3,159
1,405
4,759
8,253
5,039
7,140
3,146
2,676
4,871
7,353
12,466
8,437
8,666
8,827
12,485
17,156
13,179
11,992
12,969
7,943
19,325
19,3257,94312,96911,99213,17917,15612,4858,8278,6668,43712,4667,3534,8712,6763,1467,1405,0398,2534,7591,4053,1592,0252,0251,801
       Other Current Liabilities 
872
191
191
5,267
3,654
7,281
10,948
16,083
15,462
12,168
10,565
13,881
25,540
19,990
18,463
27,797
28,323
23,864
18,808
27,995
33,206
33,584
41,855
52,790
52,79041,85533,58433,20627,99518,80823,86428,32327,79718,46319,99025,54013,88110,56512,16815,46216,08310,9487,2813,6545,267191191872
   > Long-term Liabilities 
72,412
0
0
72,654
166,804
288
3,766
3,788
5,046
5,108
5,057
4,955
77,149
77,374
77,600
201,038
201,886
202,701
203,522
204,353
206,030
206,290
206,980
108,287
108,287206,980206,290206,030204,353203,522202,701201,886201,03877,60077,37477,1494,9555,0575,1085,0463,7883,766288166,80472,6540072,412
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
72,350
72,742
73,138
196,753
0
198,763
199,767
0
0
0
0
0
00000199,767198,7630196,75373,13872,74272,350000000000000
       Other Liabilities 
0
195
195
227
184
206
156
113
82
58
25
31
25
19
12
0
0
0
0
0
0
0
0
0
000000000121925312558821131562061842271951950
> Total Stockholder Equity
-23,987
-38,658
33,594
-52,950
-65,029
241,882
208,923
173,071
270,621
450,994
414,488
362,995
297,677
253,772
195,382
270,774
209,581
139,732
80,508
46,717
88,667
224,942
186,427
156,641
156,641186,427224,94288,66746,71780,508139,732209,581270,774195,382253,772297,677362,995414,488450,994270,621173,071208,923241,882-65,029-52,95033,594-38,658-23,987
   Retained Earnings -1,111,155-1,069,618-1,017,286-981,904-915,620-870,855-799,864-719,764-647,745-540,036-472,630-408,306-336,980-280,000-237,992-201,950-167,901-129,697-94,285-66,272-53,704-39,223-39,223-24,276
   Accumulated Other Comprehensive Income 
0
0
0
0
-1
19
-231,970
4
-2
42
-36
-18
-255
-1,020
-1,252
-1,596
-1,086
-414
-292
-184
4
-133
-294
533
533-294-1334-184-292-414-1,086-1,596-1,252-1,020-255-18-3642-24-231,97019-10000
   Capital Surplus 
289
0
561
754
1,244
336,145
0
0
472,569
688,939
694,519
699,988
706,233
727,417
736,665
920,109
0
940,004
951,649
0
0
0
0
0
00000951,649940,0040920,109736,665727,417706,233699,988694,519688,939472,56900336,1451,2447545610289
   Treasury Stock000000000000000000000000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue59,606
Cost of Revenue-4,987
Gross Profit54,61954,619
 
Operating Income (+$)
Gross Profit54,619
Operating Expense-295,720
Operating Income-241,101-241,101
 
Operating Expense (+$)
Research Development110,575
Selling General Administrative173,494
Selling And Marketing Expenses0
Operating Expense295,720284,069
 
Net Interest Income (+$)
Interest Income0
Interest Expense-29,712
Other Finance Cost-847
Net Interest Income-28,865
 
Pretax Income (+$)
Operating Income-241,101
Net Interest Income-28,865
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-259,027-223,175
EBIT - interestExpense = -259,027
-259,027
-232,428
Interest Expense29,712
Earnings Before Interest and Taxes (EBIT)-229,315-229,315
Earnings Before Interest and Taxes (EBITDA)-227,434
 
After tax Income (+$)
Income Before Tax-259,027
Tax Provision-3,113
Net Income From Continuing Ops-267,875-262,140
Net Income-262,140
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses300,707
Total Other Income/Expenses Net-17,92628,865
 

Technical Analysis of Arcutis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Arcutis. The general trend of Arcutis is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Arcutis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Arcutis Biotherapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 12.95 < 13.50 < 15.21.

The bearish price targets are: 11.44 > 11.33 > 11.22.

Tweet this
Arcutis Biotherapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Arcutis Biotherapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Arcutis Biotherapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Arcutis Biotherapeutics Inc. The current macd is 0.76181465.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Arcutis price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Arcutis. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Arcutis price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Arcutis Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartArcutis Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Arcutis Biotherapeutics Inc. The current adx is 42.92.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Arcutis shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Arcutis Biotherapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Arcutis Biotherapeutics Inc. The current sar is 11.64.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Arcutis Biotherapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Arcutis Biotherapeutics Inc. The current rsi is 62.23. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Arcutis Biotherapeutics Inc Daily Relative Strength Index (RSI) ChartArcutis Biotherapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Arcutis Biotherapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Arcutis price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Arcutis Biotherapeutics Inc Daily Stochastic Oscillator ChartArcutis Biotherapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Arcutis Biotherapeutics Inc. The current cci is 68.22.

Arcutis Biotherapeutics Inc Daily Commodity Channel Index (CCI) ChartArcutis Biotherapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Arcutis Biotherapeutics Inc. The current cmo is 22.52.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Arcutis Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartArcutis Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Arcutis Biotherapeutics Inc. The current willr is -24.62006079.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Arcutis is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Arcutis Biotherapeutics Inc Daily Williams %R ChartArcutis Biotherapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Arcutis Biotherapeutics Inc. The current atr is 0.81449931.

Arcutis Biotherapeutics Inc Daily Average True Range (ATR) ChartArcutis Biotherapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Arcutis Biotherapeutics Inc. The current obv is 81,508,074.

Arcutis Biotherapeutics Inc Daily On-Balance Volume (OBV) ChartArcutis Biotherapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Arcutis Biotherapeutics Inc. The current mfi is 67.97.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Arcutis Biotherapeutics Inc Daily Money Flow Index (MFI) ChartArcutis Biotherapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Arcutis Biotherapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-29STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Arcutis Biotherapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Arcutis Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.233
Ma 20Greater thanMa 5011.591
Ma 50Greater thanMa 10010.260
Ma 100Greater thanMa 20010.029
OpenGreater thanClose12.250
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Arcutis with someone you think should read this too:
  • Are you bullish or bearish on Arcutis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Arcutis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Arcutis Biotherapeutics Inc

I send you an email if I find something interesting about Arcutis Biotherapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Arcutis Biotherapeutics Inc.

Receive notifications about Arcutis Biotherapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.